• Precision BioSciences, Inc. (NASDAQ: DTIL) reported an Earnings per Share (EPS) of -$2.735, falling short of the estimated EPS of -$2.09.
• DTIL’s debt-to-equity ratio is 0.47, indicating a moderate level of debt relative to equity.

Precision BioSciences, Inc. (NASDAQ: DTIL) focuses on developing in vivo gene editing therapies through its proprietary ARCUS® platform. On March 26, 2025, DTIL revealed an earnings per share (EPS) of -$2.735, below the projected EPS of -$2.09. Actual revenue fell short at $3.471 million, while estimated revenue stood at $4.275 million.

The price-to-sales ratio for DTIL is 0.53, suggesting that market values the company’s sales at just over half of its current market price. This cautious stance from investors reflects uncertainty about DTIL’s capacity to generate revenue in the future. Additionally, the enterprise value to sales ratio stands negative at -0.38, indicating liabilities surpass its market cap and cash.

Further insight into DTIL reveals its enterprise value to operating cash flow ratio of 0.59, implying a relative efficiency in cash generation from operations.

DTIL’s debt-to-equity ratio of 0.47 signifies moderate debt reliance for operational financing. Furthermore, DTIL possesses a strong current ratio of 9.22, indicating solid coverage of short-term liabilities with assets.